IO Biotech is a clinical-stage biotech company developing immune-modulating cancer therapies. It utilizes the T-win technology platform and develops IO102-IO103 designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1.